Published in Neuro Oncol on November 15, 2012
A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat Rev Cancer (2015) 1.40
Malignant peripheral nerve sheath tumors. Oncologist (2014) 1.23
Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. Oncotarget (2014) 1.04
Chemotherapy for the treatment of malignant peripheral nerve sheath tumors in neurofibromatosis 1: a 10-year institutional review. Orphanet J Rare Dis (2013) 0.98
Trp53 haploinsufficiency modifies EGFR-driven peripheral nerve sheath tumorigenesis. Am J Pathol (2014) 0.93
Treatment of orthotopic malignant peripheral nerve sheath tumors with oncolytic herpes simplex virus. Neuro Oncol (2014) 0.84
Aggressive malignant peripheral nerve sheath tumor of the lower limb in a patient with neurofibromatosis-1 and multiple spinal cord neurofibromas. Hippokratia (2015) 0.82
Bone and soft tissue ablation. Semin Intervent Radiol (2014) 0.80
Malignant peripheral nerve sheath tumors of the head and neck: a case series and literature review. Case Rep Otolaryngol (2014) 0.79
Methylated RASSF1A in malignant peripheral nerve sheath tumors identifies neurofibromatosis type 1 patients with inferior prognosis. Neuro Oncol (2014) 0.79
Incidences of Primary Soft Tissue Sarcoma Diagnosed on Extremities and Trunk Wall: A Population-Based Study in Taiwan. Medicine (Baltimore) (2015) 0.78
Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors. J Neurosurg (2016) 0.78
STAT1 and NF-κB Inhibitors Diminish Basal Interferon-Stimulated Gene Expression and Improve the Productive Infection of Oncolytic HSV in MPNST Cells. Mol Cancer Res (2016) 0.78
Malignant peripheral nerve sheath tumour of the maxilla. Case Rep Otolaryngol (2014) 0.75
Prospect and progress of oncolytic viruses for treating peripheral nerve sheath tumors. Expert Opin Orphan Drugs (2015) 0.75
Perfusion single photon emission computed tomography in a mouse model of neurofibromatosis type 1: towards a biomarker of neurologic deficits. J Cereb Blood Flow Metab (2015) 0.75
Chemically Induced Oncogenesis in the Peripheral Nervous System Is Suppressed in Congenic BDIX.BDIV-Mss1 and -Mss7 Rats. G3 (Bethesda) (2015) 0.75
Radical Surgery with a Therapeutic Lymphadenectomy in a Rare Case of MPNST with Synchronous Regional and Non Regional Lymph Node Metastasis. Indian J Surg Oncol (2013) 0.75
Combinatorial therapeutic targeting of BMP2 and MEK-ERK pathways in NF1-associated malignant peripheral nerve sheath tumors. Oncotarget (2016) 0.75
Malignant Peripheral Nerve Sheath Tumor of Prostate: A Rare Case Report and Literature Review. Case Rep Urol (2016) 0.75
Malignant peripheral nerve sheath tumor of the vulva, an unusual differential diagnosis for vulvar mass. Int J Surg Case Rep (2014) 0.75
Gender dimorphism and age of onset in malignant peripheral nerve sheath tumor preclinical models and human patients. BMC Cancer (2014) 0.75
Histopathologic Evaluation of Atypical Neurofibromatous Tumors and Their Transformation into Malignant Peripheral Nerve Sheath Tumor in Neurofibromatosis 1 Patients - A Consensus Overview. Hum Pathol (2017) 0.75
Targeting group I p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis. Oncogene (2017) 0.75
Outcomes of Treatment for Malignant Peripheral Nerve Sheath Tumors: Different Clinical Features Associated with Neurofibromatosis Type 1. Cancer Res Treat (2016) 0.75
Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer (1986) 8.57
Gene for von Recklinghausen neurofibromatosis is in the pericentromeric region of chromosome 17. Science (1987) 5.11
Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet (2002) 5.06
International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res (2002) 4.27
Long-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms. N Engl J Med (1986) 4.18
Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat (2000) 3.87
Development and validation of MIX: comprehensive free software for meta-analysis of causal research data. BMC Med Res Methodol (2006) 3.67
Mouse models of tumor development in neurofibromatosis type 1. Science (1999) 3.40
Malignant peripheral nerve sheath tumor: analysis of treatment outcome. Int J Radiat Oncol Biol Phys (1998) 2.99
Malignant peripheral nerve sheath tumors: prognostic factors and survival in a series of patients treated at a single institution. Cancer (2006) 2.98
Mouse tumor model for neurofibromatosis type 1. Science (1999) 2.89
Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet (2001) 2.78
Malignant peripheral nerve sheath tumors of the buttock and lower extremity. A study of 43 cases. Cancer (1990) 2.74
Pediatric malignant peripheral nerve sheath tumor: the Italian and German soft tissue sarcoma cooperative group. J Clin Oncol (2005) 2.26
SARCOMAS OF THE PERIPHERAL NERVES AND SOMATIC SOFT TISSUES ASSOCIATED WITH MULTIPLE NEUROFIBROMATOSIS (VON RECKLINGHAUSEN'S DISEASE). Cancer (1963) 2.23
Malignant peripheral nerve sheath tumors (MPNST): the Mayo Clinic experience. Ann Surg Oncol (2011) 2.06
Malignant schwannoma--clinical characteristics, survival, and response to therapy. Cancer (1981) 2.04
Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg (2009) 2.04
Malignant peripheral nerve sheath tumors in patients with and without neurofibromatosis. Eur J Surg Oncol (1995) 1.90
Malignant peripheral nerve sheath tumors (malignant schwannomas) in children. Am J Surg Pathol (1992) 1.81
Outcomes in a consecutive series of 111 surgically treated plexal tumors: a review of the experience at the Louisiana State University Health Sciences Center. J Neurosurg (2001) 1.81
Large-scale molecular comparison of human schwann cells to malignant peripheral nerve sheath tumor cell lines and tissues. Cancer Res (2006) 1.80
Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics (2007) 1.71
p53 expression in neurofibroma and malignant peripheral nerve sheath tumor. An immunohistochemical study of sporadic and NF1-associated tumors. Am J Clin Pathol (1996) 1.67
Association between benign and malignant peripheral nerve sheath tumors in NF1. Neurology (2005) 1.65
Malignant Peripheral Nerve Sheath Tumor: molecular pathogenesis and current management considerations. J Surg Oncol (2008) 1.64
PRIMARY MALIGNANT NEOPLASMS OF NERVES (MALIGNANT NEURILEMOMAS) IN PATIENTS WITHOUT MANIFESTATIONS OF MULTIPLE NEUROFIBROMATOSIS (VON RECKLINGHAUSEN'S DISEASE). Cancer (1963) 1.60
Malignant peripheral nerve sheath tumors with divergent differentiation. Cancer (1984) 1.57
A molecular map of mesenchymal tumors. Genome Biol (2005) 1.52
Malignant peripheral nerve sheath tumors associated with neurofibromatosis type 1: a clinicopathologic and molecular study of 17 patients. Arch Dermatol (2001) 1.50
Malignant peripheral nerve sheath tumors of the head and neck: analysis of prognostic factors. Otolaryngol Head Neck Surg (2000) 1.48
Survival in malignant schwannoma. An 18-year study. Cancer (1971) 1.45
Survival data for patients with malignant schwannoma. Clin Orthop Relat Res (2004) 1.43
Malignant peripheral nerve sheath tumors. Neurosurg Clin N Am (2008) 1.42
TP53 mutations are frequent in malignant NF1 tumors. Genes Chromosomes Cancer (1994) 1.37
Malignant peripheral nerve sheath tumors of cranial nerves and intracranial contents: a clinicopathologic study of 17 cases. Am J Surg Pathol (2009) 1.36
Neurofibrosarcoma. Cancer (1980) 1.33
Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors. Curr Oncol Rep (2009) 1.32
Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours. Eur J Nucl Med Mol Imaging (2006) 1.32
Life expectancy, mortality and prognostic factors in neurofibromatosis type 1. A twelve-year follow-up of an epidemiological study in Göteborg, Sweden. Acta Derm Venereol (1995) 1.31
Epithelioid malignant schwannoma. A study of 14 cases. Virchows Arch A Pathol Anat Histopathol (1986) 1.28
Malignant schwannoma of the head and neck. Am J Surg (1992) 1.28
Mortality in neurofibromatosis 1: in North West England: an assessment of actuarial survival in a region of the UK since 1989. Eur J Hum Genet (2011) 1.27
Subdiaphragmatic and intrathoracic paraspinal malignant peripheral nerve sheath tumors: a clinicopathologic study of 25 patients and 26 tumors. Cancer (1998) 1.27
Rb and TP53 pathway alterations in sporadic and NF1-related malignant peripheral nerve sheath tumors. Lab Invest (2001) 1.26
Germline and somatic NF1 gene mutation spectrum in NF1-associated malignant peripheral nerve sheath tumors (MPNSTs). Hum Mutat (2008) 1.25
Plexiform neurofibroma with and without associated malignant peripheral nerve sheath tumor: a clinicopathologic and immunohistochemical analysis of 54 cases. Mod Pathol (1998) 1.22
Array-based comparative genomic hybridization identifies CDK4 and FOXM1 alterations as independent predictors of survival in malignant peripheral nerve sheath tumor. Clin Cancer Res (2011) 1.20
Cytogenetic characterization of peripheral nerve sheath tumours: a report of the CHAMP study group. J Pathol (2000) 1.18
Histopathology and clinical outcome of NF1-associated vs. sporadic malignant peripheral nerve sheath tumors. J Neurooncol (2006) 1.18
Neurogenic sarcomas: experience at the University of Toronto. Neurosurgery (1998) 1.13
Malignant soft tissue tumors of nerve sheath origin. J Surg Oncol (1984) 1.13
Malignant peripheral nerve sheath tumors of the head and neck: management of 10 cases and literature review. Head Neck (2007) 1.12
Further evidence of the increased risk for malignant peripheral nerve sheath tumour from a Scottish cohort of patients with neurofibromatosis type 1. J Med Genet (2007) 1.12
Germline and somatic NF1 mutations in sporadic and NF1-associated malignant peripheral nerve sheath tumours. J Pathol (2009) 1.11
Expression of p27(kip) and other cell cycle regulators in malignant peripheral nerve sheath tumors and neurofibromas: the emerging role of p27(kip) in malignant transformation of neurofibromas. Am J Pathol (1999) 1.11
Survival in Malignant Peripheral Nerve Sheath Tumours: A Comparison between Sporadic and Neurofibromatosis Type 1-Associated Tumours. Sarcoma (2009) 1.10
Genomic imbalances of 7p and 17q in malignant peripheral nerve sheath tumors are clinically relevant. Genes Chromosomes Cancer (1999) 1.09
MMP-13 and p53 in the progression of malignant peripheral nerve sheath tumors. Neoplasia (2007) 1.07
Malignant nerve sheath tumors of the head and neck: a combined experience from two university hospitals. Laryngoscope (1991) 1.06
Topoisomerase-II alpha is upregulated in malignant peripheral nerve sheath tumors and associated with clinical outcome. J Clin Oncol (2003) 1.06
Frequent genomic imbalances in chromosomes 17, 19, and 22q in peripheral nerve sheath tumours detected by comparative genomic hybridization analysis. J Pathol (2002) 1.06
Gene expression profiling reveals unique molecular subtypes of Neurofibromatosis Type I-associated and sporadic malignant peripheral nerve sheath tumors. Brain Pathol (2004) 1.06
Tumors of the peripheral nervous system. CA Cancer J Clin (1983) 1.04
Early outcomes for malignant peripheral nerve sheath tumor treated with chemotherapy. Am J Clin Oncol (2011) 1.03
Subclassification of nerve sheath tumors by gene expression profiling. Brain Pathol (2004) 1.03
Identification of a novel amplicon at distal 17q containing the BIRC5/SURVIVIN gene in malignant peripheral nerve sheath tumours. J Pathol (2006) 1.02
Prognostic significance of p14ARF, p15INK4b, and p16INK4a inactivation in malignant peripheral nerve sheath tumors. Clin Cancer Res (2011) 1.01
Analysis of chromosomal imbalances in sporadic and NF1-associated peripheral nerve sheath tumors by comparative genomic hybridization. Genes Chromosomes Cancer (1999) 0.99
Neurofibromatosis type I and malignancy: review of 32 pediatric cases treated at a single institution. Med Pediatr Oncol (1994) 0.98
Malignant peripheral nerve-sheath tumors (malignant schwannomas). An immunohistochemical study of 29 cases. Am J Surg Pathol (1985) 0.97
Non-metastatic unresected paediatric non-rhabdomyosarcoma soft tissue sarcomas: results of a pooled analysis from United States and European groups. Eur J Cancer (2010) 0.96
Gain of 17q24-qter detected by comparative genomic hybridization in malignant tumors from patients with von Recklinghausen's neurofibromatosis. Cancer Res (1996) 0.96
Mortality associated with neurofibromatosis type 1: a study based on Italian death certificates (1995-2006). Orphanet J Rare Dis (2011) 0.96
cDNA microarray analysis of cancer associated gene expression profiles in malignant peripheral nerve sheath tumours. J Clin Pathol (2006) 0.95
Gains in chromosomes 7, 8q, 15q and 17q are characteristic changes in malignant but not in benign peripheral nerve sheath tumors from patients with Recklinghausen's disease. Cancer Lett (2000) 0.95
Malignant peripheral nerve sheath tumors. Neurosurg Clin N Am (2004) 0.94
Constitutional NF1 mutations in neurofibromatosis 1 patients with malignant peripheral nerve sheath tumors. Hum Mutat (2003) 0.94
Alterations at chromosome 17 loci in peripheral nerve sheath tumors. J Neuropathol Exp Neurol (1995) 0.94
Malignant peripheral nerve sheath tumors: the St. Jude Children's Research Hospital experience. Ann Surg Oncol (1995) 0.93
Clinical relevance of pathological grades of malignant peripheral nerve sheath tumor: a multi-institution TMTS study of 56 cases in Northern Japan. Ann Surg Oncol (2007) 0.93
Microarray-based identification of tenascin C and tenascin XB, genes possibly involved in tumorigenesis associated with neurofibromatosis type 1. Clin Cancer Res (2007) 0.93
Expression patterns of cell cycle components in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. J Neuropathol Exp Neurol (2005) 0.90
Treatment of children with neurogenic sarcoma. Experience at the Children's Hospital of Philadelphia, 1958-1984. Cancer (1987) 0.90
Malignant peripheral nerve sheath tumours: high Ki67 labelling index is the significant prognostic indicator. Histopathology (2001) 0.89
Identification of p53 as a strong predictor of survival for patients with malignant peripheral nerve sheath tumors. Neuro Oncol (2009) 0.89
A consecutive series of 30 malignant schwannomas. Survival in relation to clinico-pathological parameters and treatment. Acta Pathol Microbiol Immunol Scand A (1984) 0.88
Biallelic inactivation of TP53 rarely contributes to the development of malignant peripheral nerve sheath tumors. Genes Chromosomes Cancer (2001) 0.88
Chromosome band 9p21 is frequently altered in malignant peripheral nerve sheath tumors: studies of CDKN2A and other genes of the pRB pathway. Genes Chromosomes Cancer (1999) 0.88
Malignant tumors of nerve sheath origin. Cancer (1980) 0.88
Genomic changes in chromosomes 10, 16, and X in malignant peripheral nerve sheath tumors identify a high-risk patient group. J Clin Oncol (2010) 0.88
Computer-assisted cytogenetic analysis of 51 malignant peripheral-nerve-sheath tumors: sporadic vs. neurofibromatosis-type-1-associated malignant schwannomas. Int J Cancer (1999) 0.87
Expression and significance of EGFR in malignant peripheral nerve sheath tumor. J Neurooncol (2009) 0.86
Frequent EGFR Positivity and Overexpression in High-Grade Areas of Human MPNSTs. Sarcoma (2008) 0.86
Aberrant expression of CHFR in malignant peripheral nerve sheath tumors. Mod Pathol (2006) 0.84
Malignant peripheral nerve sheath tumors in children: a single-institution twenty-year experience. J Pediatr Hematol Oncol (2000) 0.83
Malignant peripheral nerve sheath tumors in childhood: 13 cases from a single center. J Pediatr Hematol Oncol (2012) 0.81
Malignant peripheral nerve tumors: a clinicopathological and electron microscopic study. Jpn J Clin Oncol (1984) 0.81
Malignant peripheral nerve sheath tumours in NF1: improved survival in women and in recent years. Eur J Cancer (2011) 0.80
The p53 gene in soft tissue sarcomas: prognostic value of DNA sequencing versus immunohistochemistry. Anticancer Res (1998) 0.79
The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer (2007) 9.81
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
Fusion genes and rearranged genes as a linear function of chromosome aberrations in cancer. Nat Genet (2004) 5.75
Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer (2006) 3.11
Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. J Clin Oncol (2012) 2.67
CGH-Explorer: a program for analysis of array-CGH data. Bioinformatics (2004) 2.65
PtdIns(3)P controls cytokinesis through KIF13A-mediated recruitment of FYVE-CENT to the midbody. Nat Cell Biol (2010) 2.33
Chordoma of the mobile spine: fifty years of experience. Spine (Phila Pa 1976) (2006) 2.23
Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet (2013) 2.21
Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol (2005) 2.17
Low heart rates predict incident atrial fibrillation in healthy middle-aged men. Circ Arrhythm Electrophysiol (2013) 2.12
Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res (2005) 2.09
Treatment and outcome of recurrent osteosarcoma: experience at Rizzoli in 235 patients initially treated with neoadjuvant chemotherapy. Acta Oncol (2005) 1.94
Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional-based study. J Pathol (2010) 1.91
Postrelapse survival in osteosarcoma of the extremities: prognostic factors for long-term survival. J Clin Oncol (2003) 1.79
A phosphatidylinositol 3-kinase class III sub-complex containing VPS15, VPS34, Beclin 1, UVRAG and BIF-1 regulates cytokinesis and degradative endocytic traffic. Exp Cell Res (2010) 1.75
Meta-analysis identifies four new loci associated with testicular germ cell tumor. Nat Genet (2013) 1.74
Copynumber: Efficient algorithms for single- and multi-track copy number segmentation. BMC Genomics (2012) 1.74
The Genomic HyperBrowser: inferential genomics at the sequence level. Genome Biol (2010) 1.74
A CpG island hypermethylation profile of primary colorectal carcinomas and colon cancer cell lines. Mol Cancer (2004) 1.72
The order of genetic events associated with colorectal cancer progression inferred from meta-analysis of copy number changes. Genes Chromosomes Cancer (2006) 1.67
Autophagy in tumour suppression and promotion. Mol Oncol (2009) 1.64
ColoGuideEx: a robust gene classifier specific for stage II colorectal cancer prognosis. Gut (2012) 1.63
Three epigenetic biomarkers, GDF15, TMEFF2, and VIM, accurately predict bladder cancer from DNA-based analyses of urine samples. Clin Cancer Res (2010) 1.62
Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. Eur J Cancer (2005) 1.62
Structural and numerical chromosome changes in colon cancer develop through telomere-mediated anaphase bridges, not through mitotic multipolarity. Proc Natl Acad Sci U S A (2005) 1.61
Platelet-derived growth factors enhance proliferation of human stromal stem cells. Biomaterials (2003) 1.61
Antibody crossreactivity between the tumour suppressor PHLPP1 and the proto-oncogene β-catenin. EMBO Rep (2012) 1.57
Upper normal blood pressures predict incident atrial fibrillation in healthy middle-aged men: a 35-year follow-up study. Hypertension (2012) 1.57
Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression. BMC Genomics (2009) 1.57
Prevalence estimates of recurrent balanced cytogenetic aberrations and gene fusions in unselected patients with neoplastic disorders. Genes Chromosomes Cancer (2005) 1.57
Reasons for terminating an exercise test provide independent prognostic information: 2014 apparently healthy men followed for 26 years. Eur Heart J (2005) 1.55
Oncogenicity of the developmental transcription factor Sox9. Cancer Res (2012) 1.55
Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Clin Cancer Res (2011) 1.53
Differentiation of human embryonal carcinomas in vitro and in vivo reveals expression profiles relevant to normal development. Cancer Res (2005) 1.52
NVP-BEZ235 as a new therapeutic option for sarcomas. Clin Cancer Res (2010) 1.52
Outcome of advanced, unresectable conventional central chondrosarcoma. Cancer (2014) 1.51
ADAMTS1, CRABP1, and NR3C1 identified as epigenetically deregulated genes in colorectal tumorigenesis. Cell Oncol (2006) 1.48
Blood pressure in the neonate: three non-invasive oscillometric pressure monitors compared with invasively measured blood pressure. Acta Paediatr (2005) 1.47
MUC4 is a highly sensitive and specific marker for low-grade fibromyxoid sarcoma. Am J Surg Pathol (2011) 1.45
Clustering of deletions on chromosome 13 in benign and low-malignant lipomatous tumors. Int J Cancer (2003) 1.45
DNA methylation profiling of ovarian carcinomas and their in vitro models identifies HOXA9, HOXB5, SCGB3A1, and CRABP1 as novel targets. Mol Cancer (2007) 1.44
In Ewing's sarcoma CCN3(NOV) inhibits proliferation while promoting migration and invasion of the same cell type. Oncogene (2005) 1.44
Identification of a novel, recurrent HEY1-NCOA2 fusion in mesenchymal chondrosarcoma based on a genome-wide screen of exon-level expression data. Genes Chromosomes Cancer (2011) 1.44
Histological heterogeneity of Ewing's sarcoma/PNET: an immunohistochemical analysis of 415 genetically confirmed cases with clinical support. Virchows Arch (2009) 1.39
Connexin43 acts as a colorectal cancer tumor suppressor and predicts disease outcome. Int J Cancer (2011) 1.39
MiR-9, -31, and -182 deregulation promote proliferation and tumor cell survival in colon cancer. Neoplasia (2012) 1.39
Cisplatin-induced long-term hearing impairment is associated with specific glutathione s-transferase genotypes in testicular cancer survivors. J Clin Oncol (2007) 1.38
Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma. Nat Genet (2012) 1.37
Clinical outcome of central conventional chondrosarcoma. J Surg Oncol (2012) 1.37
Local recurrence and local control of non-metastatic osteosarcoma of the extremities: a 27-year experience in a single institution. J Surg Oncol (2007) 1.36
Genetic tumor markers with prognostic impact in Dukes' stages B and C colorectal cancer patients. J Clin Oncol (2003) 1.36
The expression of ccn3(nov) gene in musculoskeletal tumors. Am J Pathol (2002) 1.35
miR-34a predicts survival of Ewing's sarcoma patients and directly influences cell chemo-sensitivity and malignancy. J Pathol (2012) 1.34
Genetic and epigenetic changes of components affecting the WNT pathway in colorectal carcinomas stratified by microsatellite instability. Neoplasia (2005) 1.33
Distinct epigenetic phenotypes in seminomatous and nonseminomatous testicular germ cell tumors. Oncogene (2002) 1.32
Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers. Mol Cancer (2008) 1.31
Fine-needle aspiration of neurilemoma (schwannoma). A clinicocytopathologic study of 116 patients. Diagn Cytopathol (2006) 1.29
Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor. Int J Cancer (2006) 1.29
Comprehensive genetic analysis identifies a pathognomonic NAB2/STAT6 fusion gene, nonrandom secondary genomic imbalances, and a characteristic gene expression profile in solitary fibrous tumor. Genes Chromosomes Cancer (2013) 1.29
Chordoma of the mobile spine and sacrum: a retrospective analysis of a series of patients surgically treated at two referral centers. Ann Surg Oncol (2009) 1.28
Synovial sarcoma: retrospective analysis of 250 patients treated at a single institution. Cancer (2009) 1.26
Membrane remodeling by the PX-BAR protein SNX18 promotes autophagosome formation. J Cell Biol (2013) 1.26
DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset. PLoS One (2010) 1.26
Identifying clusters in genomics data by recursive partitioning. Stat Appl Genet Mol Biol (2013) 1.25
New insights into testicular germ cell tumorigenesis from gene expression profiling. Cancer Res (2002) 1.25
Preclinical in vivo study of new insulin-like growth factor-I receptor--specific inhibitor in Ewing's sarcoma. Clin Cancer Res (2007) 1.25
The chimeric FUS/CREB3l2 gene is specific for low-grade fibromyxoid sarcoma. Genes Chromosomes Cancer (2004) 1.24
Molecular genetic characterization of the EWS/ATF1 fusion gene in clear cell sarcoma of tendons and aponeuroses. Int J Cancer (2002) 1.24
Gene expression profiles of primary colorectal carcinomas, liver metastases, and carcinomatoses. Mol Cancer (2007) 1.23
Molecular cytogenetic characterization of recurrent translocation breakpoints in bizarre parosteal osteochondromatous proliferation (Nora's lesion). Hum Pathol (2004) 1.22
Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas. Mol Cancer (2011) 1.22
Fusion of the FUS and BBF2H7 genes in low grade fibromyxoid sarcoma. Hum Mol Genet (2003) 1.22
Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. J Clin Oncol (2013) 1.21
Emerging drugs for high-grade osteosarcoma. Expert Opin Emerg Drugs (2010) 1.21
TCF21 and PCDH17 methylation: An innovative panel of biomarkers for a simultaneous detection of urological cancers. Epigenetics (2011) 1.20
Cancer risk with folic acid supplements: a systematic review and meta-analysis. BMJ Open (2012) 1.20
The Genomic HyperBrowser: an analysis web server for genome-scale data. Nucleic Acids Res (2013) 1.20
Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol Cancer (2009) 1.20
Testicular germ cell tumor susceptibility associated with the UCK2 locus on chromosome 1q23. Hum Mol Genet (2013) 1.19
miRNA expression profile in human osteosarcoma: role of miR-1 and miR-133b in proliferation and cell cycle control. Int J Oncol (2012) 1.18
No genomic aberrations in Langerhans cell histiocytosis as assessed by diverse molecular technologies. Genes Chromosomes Cancer (2009) 1.18
Absence of mutations of the BRAF gene in malignant melanoma of soft parts (clear cell sarcoma of tendons and aponeuroses). Cancer Genet Cytogenet (2005) 1.17
FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer. Genes Chromosomes Cancer (2011) 1.17
RAS signaling in colorectal carcinomas through alteration of RAS, RAF, NF1, and/or RASSF1A. Neoplasia (2008) 1.17
UVRAG mutations associated with microsatellite unstable colon cancer do not affect autophagy. Autophagy (2010) 1.16
Two genetic pathways, t(1;10) and amplification of 3p11-12, in myxoinflammatory fibroblastic sarcoma, haemosiderotic fibrolipomatous tumour, and morphologically similar lesions. J Pathol (2009) 1.15
Hematogenous micrometastases in osteosarcoma patients. Clin Cancer Res (2005) 1.15
Effect of TP53 Arg72Pro and MDM2 SNP309 polymorphisms on the risk of high-grade osteosarcoma development and survival. Clin Cancer Res (2009) 1.15
Radiation-induced sarcoma: 25-year experience from the Norwegian Radium Hospital. Acta Oncol (2008) 1.14
Bisphosphonate treatment of aggressive primary, recurrent and metastatic Giant Cell Tumour of Bone. BMC Cancer (2010) 1.13
Genome signatures of colon carcinoma cell lines. Cancer Genet Cytogenet (2004) 1.13
Transcriptome instability in colorectal cancer identified by exon microarray analyses: Associations with splicing factor expression levels and patient survival. Genome Med (2011) 1.13
Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma. PLoS One (2012) 1.13
Novel genomic aberrations in testicular germ cell tumors by array-CGH, and associated gene expression changes. Cell Oncol (2006) 1.13
Differentially amplified chromosome 12 sequences in low- and high-grade osteosarcoma. Genes Chromosomes Cancer (2002) 1.12
Molecular mechanisms of CD99-induced caspase-independent cell death and cell-cell adhesion in Ewing's sarcoma cells: actin and zyxin as key intracellular mediators. Oncogene (2004) 1.12